High LAG3 + expression has been associated with poor prognosis in non-small cell lung cancer (He et al. 2017; Shepherd et al. 2022), renal cell cancer (Giraldo et al. 2015), hepatocellular cancer (Guo et al. 2020), and pancreatic cancer (Seifert et al. 2021) but with favorable prognosis in breast cancer (Burugu et al. 2017), colon cancer (Rhyner Agocs et al. 2021), and esophageal cancer (Zhang et al. 2018; Gebauer et al. 2020). This evidence concerns the gene LAG3 and non-small cell lung carcinoma.